Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0002355
UniProt IDP28062
Primary gene name(s)PSMB8
Synonym gene name(s)LMP7, PSMB5i, RING10, Y2
Protein nameProteasome subunit beta type-8
Protein functionThe proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1, E2 by isoform 2, E1 results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes. {ECO:0000269|PubMed:16423992, ECO:0000269|PubMed:19443843, ECO:0000269|PubMed:21881205, ECO:0000269|PubMed:8163024}.
Subcellular locationCytoplasm {ECO:0000255|PROSITE-ProRule:PRU00809}. Nucleus {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P28062
Gene Ontology
(Biological Process)
Complete annatation
anaphase-promoting complex-dependent catabolic process [GO:0031145];
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479];
fat cell differentiation [GO:0045444];
Fc-epsilon receptor signaling pathway [GO:0038095];
MAPK cascade [GO:0000165];
negative regulation of canonical Wnt signaling pathway [GO:0090090];
negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436];
NIK/NF-kappaB signaling [GO:0038061];
positive regulation of canonical Wnt signaling pathway [GO:0090263];
positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition [GO:0051437];
proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161];
protein polyubiquitination [GO:0000209];
regulation of cellular amino acid metabolic process [GO:0006521];
regulation of endopeptidase activity [GO:0052548];
regulation of mRNA stability [GO:0043488];
stimulatory C-type lectin receptor signaling pathway [GO:0002223];
T cell receptor signaling pathway [GO:0050852];
tumor necrosis factor-mediated signaling pathway [GO:0033209];
type I interferon signaling pathway [GO:0060337];
viral process [GO:0016032];
Wnt signaling pathway, planar cell polarity pathway [GO:0060071]
Gene Ontology
(Molecular Function)
Complete annatation
threonine-type endopeptidase activity [GO:0004298]
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
extracellular exosome [GO:0070062];
nucleoplasm [GO:0005654];
proteasome complex [GO:0000502];
proteasome core complex [GO:0005839];
spermatoproteasome complex [GO:1990111]
Protein-protein interaction111669
Phylogenetic treeP28062
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: 3.200787723; Folds changes 16h: 2.420835418; Tested: untested;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.073961376279230.001185184247479270.00421697284655512
AZA vs. DISU-0.4024333593870130.1120915096784550.661836042652969
AZA vs. IL70.3936148974632690.04076838004562610.61486428594884
AZA vs. SAHA-0.5991894765657830.01481221574355950.12621782934902
DISU vs. CD3-1.487683419398556.11546591156031e-050.000368296177190812
DISU vs. IL70.7865929133243520.001939784749959590.0415334517240081
DISU vs. SAHA-0.1949864423716330.5072822603013950.829292867447914
DMSO vs. AZA0.01005567694817520.9520867118736781
DMSO vs. CD3-1.076879014170370.0008709623156299970.00303236590824264
DMSO vs. DISU0.4101554522412860.09318682764952310.558542532800995
DMSO vs. IL70.391059868695990.02974227202926420.350558835685033
DMSO vs. SAHA-0.6147198826306520.009684572133622280.0879254136300129
HIV vs. Mock in Activation-0.1619780075419670.7945081286196120.999983755607037
HIV vs. Mock in Latency-0.05082638273763880.7578113358791690.999834320637052
IL7 vs. CD3-0.6733486145664820.03659878351245930.0853775270306956
SAHA vs. CD3-1.697002978536032.85890472340178e-062.08234384638303e-05
SAHA vs. IL7-0.9950751190933745.23459531426296e-050.00116552865239586
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
1.9 4.47E-06 1.3 0.008897827 1.5 0.00060658
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.0298157 0.93852
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
0.152 6.75E-04

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.035 0.917 0.985 1.01 0.85
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
209040_s_at 1.62 No upregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB08889 Carfilzomib approved yes inhibitor

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat enhances 9079628
Tat inhibits 9079628
Vif interacts with 9811770
reverse transcriptase degraded by 10358150
capsid downregulates 19403671
Tat upregulates 15356131
Tat binds 14550573
integrase degraded by 10893419
Tat interacts with 12419264

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa03050 Proteasome - Homo sapiens (human)